<DOC>
	<DOC>NCT02174861</DOC>
	<brief_summary>To assess the long-term safety and efficacy of AMG 334 .</brief_summary>
	<brief_title>A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.</brief_title>
	<detailed_description>This is a multicenter, open-label study to assess the long-term safety and efficacy of AMG 334. All subjects will receive an open-label AMG 334 subcutaneous (SC) dose periodically for 13 months followed by a safety follow- up visit .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1. Subject has provided informed consent prior to initiation of any studyspecific activities/procedures 2. Completed the 12week study visit and did not end IP early during the doubleblind treatment period of the AMG 334 20120295 parent study, and is appropriate for continued treatment. 1. Development of any unstable or clinically significant medical condition, laboratory or ECG abnormality following randomization into the parent study, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. 2. Systolic blood pressure (BP) 160 mm Hg and/or diastolic BP 100 mm Hg or greater at screening/Day 1. 3. Subject who used excluded concomitant medications between week 8 and week 12 of the parent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Migraine</keyword>
</DOC>